Saturday, 13 September, 2025г.
russian english deutsch french spanish portuguese czech greek georgian chinese japanese korean indonesian turkish thai uzbek

пример: покупка автомобиля в Запорожье

 

The Safety and Efficacy of Venetoclax/Obinutuzumab Combo in CLL

The Safety and Efficacy of Venetoclax/Obinutuzumab Combo in CLLУ вашего броузера проблема в совместимости с HTML5
Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.
Опубликовано: 13-12-2017
Теги: targeted oncology oncology cancer

Похожие видео
Advances in Treatments for Hematologic Malignancies Pt. 1 - Sarah Cannon

Advances in Treatments for Hematologic Malignancies Pt. 1 - Sarah Cannon04:18

Copy of Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer

Copy of Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer00:22

Dr. Peeters Discusses the Efficacy and Safety of Panitumumab Versus Cetuximab in Colorectal Cancer

Dr. Peeters Discusses the Efficacy and Safety of Panitumumab Versus Cetuximab in Colorectal Cancer00:57

Is CAR T-Cell Therapy the Future of Cancer Treatment?

Is CAR T-Cell Therapy the Future of Cancer Treatment?07:36

Мой аккаунт

Вход / Log In